The combination of folinate salts to 5-fluoruracil (5-FU)-based schedules is an established clinical routine in the landscape of the colorectal cancer treatment. The aim of this study was to investigate the pharmacological differences between the sequential administration of folinate salts (1 h before, as in clinical routine) followed by 5-FU and the simultaneous administration of both drugs. Proliferation and apoptotic assays were performed on human colon cancer cells exposed to 5-FU, calcium (CaLV) or disodium (NaLV) levofolinate or their simultaneous and sequential combination for 24 and 72h. 
INTRODUCTION
5-Fluorouracil (5-FU) and other fluoropyrimidines (e.g. capecitabine, UFT, S-1, TAS-102), still represent essential drugs in combination regimens for the adjuvant or first/second line treatment of solid tumors such as colorectal neoplasms [1] [2] [3] . Their main mechanism of action involves the inhibition of thymidylate synthase (TS) by the active metabolite 5-fluoro-deoxyuridine-monophosphate (5-FdUMP) in the presence of folate (5,10-methylenetetrahydrofolate), a required cofactor for the reaction 1 . The formation of the ternary complex 5-FdUMP/TS/folate with covalent bonds leads to the stabilization of the complex itself, with prolonged inhibition of TS catalytic activity 1, 4 . On the basis of these observations, the modulation of inhibitory effects of the fluoropyrimidines by folinate salts has been developed in preclinical and clinical settings, showing a preclinical enhancement [5] [6] [7] and a better clinical response to 5-FU/levofolinate combined treatment compared to the fluoropyrimidine alone 8 .
Unfortunately, the simultaneous use of folinic acid salified with calcium, and mixed with the 5-FU, determined the precipitation of the formed calcium carbonate 9 and subsequent catheter obstruction [10] [11] [12] . Indeed, soon it became evident in patients that the simultaneous 5-FU and calcium levofolinate (CaLV) mix and infusion in a single catheter was impossible, and 5-FU and CaLV were infused with the aid of two separate pumps 10 . Thereafter, a sequential administration CaLV followed by 5-FU (administered first as bolus injection, then as continuous or chronomodulated infusions) was adopted in the clinical routine and now represents the standard therapeutic scheme to which new drugs have been added over the years, such as irinotecan, oxaliplatin, cetuximab and bevacizumab 13 .
At the beginning of 2000s, the therapeutic armamentarium included both the CaLV and the newer formulation disodium levofolinate (NaLV) 14, 15 . The latter showed comparable efficacy to the CaLV, with an objective response rate of 37.2 % in patients with advanced rectal cancer 14 . However, it was noted that in 51 evaluable patients, the Cognizant Communication Corporation
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Oncology Research E-pub use of NaLV seemed favorably associated with a best time to progression 14 . More recently, a phase II randomized study of combined infusional NaLV and 5-FU vs. the CaLV followed by 5-FU, both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer, showed the same overall response rate in both the study arms with a comparable safety 16 . The favorable toxicity profile of the simultaneous clinical combination of 5-FU and NaLV was also recently confirmed in a 24h-infusion schedule 17 . The NaLV formulation can be easily administered simultaneously to 5-FU admixed in one ambulatory pump because it does not precipitate in the solution. This characteristic may have several clinical and nursing advantages, such as a shortening of the time necessary for the administration of drugs (with a consequent decrease in human resources) and a reduced discomfort for the patient 18 , if compared to the sequential administration of CaLV followed by 5-FU.
The aims of the present study were i) to determine the effects of simultaneous administration of 5-FU and NaLV or CaLV on colon cancer cells compared to the sequential combination of the two drugs (CaLV or NaLV 1 h treatment before 5-FU administration), investigating both the antiproliferative and pro-apoptotic effects, and the changes in Thymidylate Synthetase (TYMS) and Solute Carrier Family 19 Member conducted in triplicate, considering 9 wells for each drug concentration tested.
In Vitro Combination Studies
To evaluate the type of interaction (i.e. synergistic, additive, and antagonistic) between the drugs, 5-FU combined with NaLV or CaLV was explored with two different treatment schedules for 24h and 72h at a fixed molar concentration ratio of 1:1 in HT-29 and Caco-2 cells, as follows: (A) a simultaneous exposure with 5-FU (0.1-100 µM)
plus NaLV or CaLV (0.1-100 µM) for 24h or 72h; (B) a sequential exposure with NaLV or CaLV (0.1-100 µM) given alone for 1 h, then 5-FU (0.1-100 µM) plus NaLV or CaLV (0.1-100 µM) were added for 24h or 72h. After drug exposure, the media of cell cultures were discarded and cells counted. Each experiment was conducted in triplicate, considering 9 wells for each drug concentration tested.
The effect of combination treatments was then assessed by the software CalcuSyn v. 2.0 (Biosoft, Cambridge, UK) using the method of Chou 22 . Briefly, the synergistic, additive or the antagonistic effect for 5-FU plus NaLV or CaLV was calculated on the basis of the multiple drug-effect equation, and quantified by the combination index (CI), where CI<1, CI=1 and CI>1 indicate synergism, additive effect and antagonism, respectively. Based on the classic isobologram, the CI value was calculated according to the following formula: 
Evaluation of Apoptosis
To quantify the apoptosis induced by the aforementioned pharmacological treatments, HT-29 and Caco-2 cell lines were treated for 24h alone and in combination 5-FU 2 µM, NaLV 2 µM and CaLV 2 µM (at the fixed molar concentration ratio of 1:1).
After incubation with drugs, cells were collected and analyzed using the Cell Death Detection ELISA Plus Kit (Roche, Basel, Switzerland) as per manufacturer's instructions. The optical density was measured using a Multiskan Spectrum microplate reader (Thermo Labsystems, Milan, Italy) set to a wavelength of 405 nm (with a wavelength of 490 nm correction). All experiments were repeated three times with at least three replicates per sample.
Evaluation of TYMS and SLC19A1 Gene Expression
The assessment of TYMS and SLC19A1 gene expression in tumor cellsexposed for 24h alone and in combination with 5-FU 2 µM, NaLV 2 µM and CaLV 2 µM ) was measured as follows: [(w1 x w1 x w2) x (π/6)], where w1 and w2 were the smallest and the largest tumor diameter (mm), respectively. The mice were randomized into groups of six animals (n=6) and were administered with the experimental schedules when the mean of tumor volumes was around 100 mm 3 . Data analysis was conducted by an investigator blinded to which group of animals represented treatments or controls.
Three different experiments were performed using escalating doses of 5-FU. In the first experiment, animals were randomized in four groups: group 1 (control group) was administered with vehicle alone (saline); group 2 received 5-FU 50 mg/kg i.p. once a week; group 3 received the CaLV 50 mg/kg i.p. once a week (slow infusion), followed 1h later by 5-FU 50 mg/kg i.p.; group 4 was treated with 5-FU 50 mg/kg i.p and NaLV 50 mg/kg, simultaneously in the same syringe. In the second experiment, animals were randomized in five groups: group 1 (control group) was administered with vehicle alone (saline); group 2 received 5-FU 100 mg/kg i.p. once a week; the group 3 received the CaLV 50 mg/kg i.p. once a week (slow infusion), followed 1h later by 5-FU 100 mg/kg 
Statistical Analysis
Analysis of variance (ANOVA), followed by Student-Newman-Keuls test was used to compare data among different groups in in vitro and in vivo experiments. P values less than 0.05 were considered significant. Statistical analyses were performed using the GraphPad Prism software package version 5.0.
RESULTS

5-FU Inhibited Tumor Cell Proliferation in a Time-and Concentration-Dependent Manner
The analysis of DNA extracted from both HT-29 and Caco-2 cells revealed a TS promoter genotype of TSER 2/2.
5-FU has shown a significant time-and concentration-dependent inhibitory activity on cell proliferation. Indeed, the maximum effect of 5-FU was obtained in HT-29 cells at 72h (IC50s 0.45±0.01 µM), whereas the Caco-2 cell line was slightly less sensitive to 5-FU concentrations at all the time points (e.g., 1.32±0.50 µM at 72h). 
In Vitro Studies of Simultaneous or Consecutive Combination of 5-FU and NaLV or CaLV After 24 or 72 h Exposure
In order to mimic the clinical settings of the simultaneous infusion of NaLV plus 5-FU and the consecutive administration of CaLV 1h before of 5-FU injection, both the in vitro schedules were studied at 24h and 72h.
Synergistic and Additive Effects of Simultaneous Combination of 5-FU and NaLV or CaLV After 24 h Exposure
Simultaneous exposure of HT-29 and CaCo-2 cells to different concentrations of 5-FU and NaLV for 24h showed a strong synergism for 50% fraction of affected cells (CI<1 , table 2 ). Interestingly, also the simultaneous treatments of 5-FU and CaLV for 24h in both CaCo-2 and HT-29 cells had additive effects for 50% fraction of affected cells (CI equal or around 1, table 2).
Antagonistic Effects of the Sequential Treatment of NaLV or CaLV (1 h) Followed by 5-FU After 24 h Exposure
Sequential exposure of HT-29 cells to different concentrations of NaLV (1 h before) and then 5-FU for 24 h showed an unexpected antagonism for all the percentages of fraction affected of cells (CI>1, 
Antagonistic Effects of the Sequential Treatment of NaLV or CaLV (1 h) Followed by 5-FU After 72 h Exposure
Sequential exposure of Caco-2 and HT-29 cells to different concentrations of NaLV (1 h before) and then 5-FU for 72h showed a marked antagonism for 50%
fraction of affected cells (CI>1 , table 2 ). Moreover, also the sequential treatments of CaLV (1 hour) followed by 5-FU for 72h in both cell lines were highly antagonist for half of affected cells (CI>1, table 2).
Induction of Apoptosis by the Simultaneous Combination of 5-FU and NaLV or CaLV in Colon Cancer Cells
The extent of DNA fragmentation was significantly higher after 24h in HT-29 cells treated with the simultaneous combination of 5-FU and NaLV (figure 1A; *P<0.05
vs. vehicle-treated cells) and, although in a minor extent, with the simultaneous combination of 5-FU and CaLV (figure 1B; *P<0.05 vs. vehicle-treated cells). Both NaLV and CaLV alone did not modulate the apoptotic process after 24h. Interestingly, both the sequential combinations (CaLV or NaLV followed by 5-FU) slightly enhanced the presence of chromatin fragments but they did not reach a statistical significance if compared to Caco-2 and HT-29 vehicle-treated cells ( figure 1A and B) . 
5-FU and NaLV or CaLV Simultaneous Combination Inhibited TYMS Gene Expression in Colon Cancer Cells
To study the effect of the treatment with 5-FU, NaLV and CaLV alone and in simultaneous or sequential combination on the variation of TYMS expression, the gene expression of the 5-FU target was quantified in HT-29 colon cancer cell line after 24h. 
NaLV or CaLV and 5-FU Sequential Combination Inhibited SLC19A1 Gene Expression in HT-29 Colon Cancer Cells
To investigate the effect of the treatment with 5-FU, NaLV and CaLV alone and in simultaneous or sequential combination on the variation of SLC19A1 expression was quantified in HT-29 colon cancer cell line exposed for 24 hours. Figure 5A) . However, at that day the experimental period finished due to their toxicity profiles as described below.
HT-29 Colon Cancer Tumor Xenografts In Vivo Studies
Figure 5B shows the toxicity profiles of the four different treatment schedules.
Both 5-FU and 5FU+NaLV treatments were favorable and acceptable with a minor loss of weight throughout the course of the treatment (Figure 5B) , whereas both the simultaneous 5-FU+CaLV combination and the sequential CaLV and 5-FU association caused a severe toxicity and a loss of weight that necessitated veterinary assistance at day 12 with an immediate fluid therapy (0.9% saline) and then at day 14, due to the nadir of body weight loss, the ethical sacrifice of all the animals, as suggested by guidelines (arrow, Figure 5B ). It is noteworthy that the animals belonging to the simultaneous 5FU+NaLV combination group had a similar body weight profile to those treated with 5-FU alone ( Figure 5B ).
Experiment With 5-FU Dose of 150 mg/kg
Tumors in control animals showed a rapid enlargement in their dimensions; a mean volume of 392 mm 3 was reached at day 8 when the experiment was closed Figure   6A ). On average, the simultaneous combination schedules were more effective if compared to 5-FU alone and to the sequential administration of CaLV followed by 5-FU. Interestingly after day 6 the initial response of this schedule was lost and the tumor volumes of this group of mice started to grow similarly to the controls ( Figure 6A) .
However, at that day the experimental period finished due to their toxicity profiles as described below. Figure 6B shows the toxicity profiles of the four different treatment schedules.
At this high 5-FU dose, the lack of weight is immediate for all the treated groups. Since the primary objective of this experiment was to establish the rapid antitumor effects of the schedules, the mice were sacrificed before the development of severe toxicity and weigh loss expected by the administered 5-FU dose.
DISCUSSION
The association of folinate salts to 5-FU-based schedules is an established clinical routine in the landscape of the colorectal cancer treatment because it has been experimentally proven to be active in past observations both in preclinical [5] [6] [7] and clinical settings 8, 23 .
In vitro experiments of the early nineties 7, 24 suggested that prolonged simultaneous exposure to both 5-FU and folinic acid would increase cytotoxicity in human cancer cell lines in a schedule-dependent manner. Moreover, it was also demonstrated that simultaneous prolonged exposure to folinic acid during 5-FU administration might be optimal for the intracellular formation of the stable ternary complex with thymidilate synthase, 5-FU metabolites and folinic acid derivatives 
